Kubota Pharmaceutical Holdings Co., Ltd.
Kubota Pharmaceutical Holdings Co., Ltd. (KBBTF) Company Profile & Overview
Explore Kubota Pharmaceutical Holdings Co., Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Kubota Pharmaceutical Holdings Co., Ltd. (KBBTF) Company Profile & Overview
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device, a home-based and patient self-monitoring optical coherence tomography devices to treat wet age-related macular degeneration and diabetic macular edema, which brings retinal edema and reduction in visual acuity; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.